The role of oestrogen receptor beta (ERβ) in the aetiology and treatment of type 2 diabetes mellitus.

INTRODUCTION: Challenges facing the treatment of type 2 diabetes necessitate the search for agents which act via alternative pathways to provide better therapeutic outcomes. Recently, an increasing body of evidence implicates the activation of oestrogen receptors (ERα and ERβ) in the development and treatment of underlying conditions in type 2 diabetes. This article summarizes available evidence for the involvement of oestrogen receptors in insulin secretion, insulin resistance as well as glucose uptake and highlights the potential of ERβ as a therapeutic target.

BACKGROUND: Recent studies indicate an association between the activation of each of the isoforms of ER and recent findings indicate that ERβ show promise as a potential target for antidiabetic drugs. In vitro and in vivo studies in receptor knock out mice indicate beneficial actions of selective agonists of ERβ receptor and underscore its therapeutic potential.

CONCLUSION: Studies are needed to further elucidate the exact mechanism underlying the role of ERβ activation as a therapeutic approach in the management of type 2 diabetes.